Decision Resources, Inc., one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that Bayer/Johnson & Johnson's rivaroxaban and Boehringer Ingelheim's dabigatran etexilate have the potential to become blockbusters during the next decade by fulfilling the extensive unmet need for safer and more convenient anticoagulants to prevent stroke in patients with atrial fibrillation.

According to the new Pharmacor report entitled Atrial Fibrillation, the development of new thrombin and factor Xa inhibitors, including rivaroxaban and dabigatran etexilate, will increase the proportion of anticoagulated atrial fibrillation patients from less than 60% to almost 75% from 2005 to 2015. The report also finds that new antiarrhythmics given to prevent chronic recurrences of the disease will fail to make a significant commercial impact before 2010 but Sanofi-Aventis's celivarone and Cardiome/Astellas' oral RSD-1235 -- although not yet proven -- represent the most promising new candidates in the Atrial Fibrillation prophylaxis market.

"The late-stage pipeline for drugs that prevent recurrent atrial fibrillation over the long-term is weak, and we only expect one drug to have near-term success in the acute treatment of atrial fibrillation, so the market will remain fairly static from 2005 to 2010," said Nikhil Mehta, analyst at Decision Resources, Inc. "During the latter half of the 2005-2015 study period, the development of oral anticoagulants for stroke prevention that require neither dose-adjustment nor monitoring will be the key driver of growth."

About Atrial Fibrillation

Atrial fibrillation is the most common sustained cardiac arrhythmia affecting nearly 8 million people in the world's major pharmaceutical markets, and the number of prevalent cases in the United States is set to more than double over the next 50 years. Despite the condition being a leading risk factor for stroke, atrial fibrillation is distinguished by a pressing unmet need for safe and easy-to-manage new anticoagulants.

About Decision Resources

Decision Resources, Inc. ( is a world leader in market research publications, advisory services, and consulting designed to help clients shape strategy, allocate resources, and master their chosen markets.

All company, brand, or product names contained in this document may be trademarks or registered trademarks of their respective holders.

  For more information, contact:   Elizabeth Marshall   Decision Resources, Inc.   781-296-2563 

SOURCE: Decision Resources, Inc.

CONTACT: Elizabeth Marshall of Decision Resources, Inc.,

Arizona Working to Reduce Number of Uninsured with Help to Employees of Small Businesses

View Now